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Atrial ﬁbrillation (AF) is associated with substantial morbidity, mortality, and economic burden and confers a lifetime risk
of up to 25%. Current medical management involves thromboembolism prevention, rate, and rhythm control. An increased
understanding of AF pathophysiology has led to enhanced pharmacological and medical therapies; however this is often limited
by toxicity, variable symptom control, and inability to modulate the atrial substrate. Surgical AF ablation has been available since
the original description of the Cox Maze procedure, either as a standaloneor concomitant intervention. Advances in novel energy
delivery systems have allowed the development of less technically demanding procedures potentially eliminating the need for
median sternotomy and cardiopulmonary bypass. Variations in the deﬁnition, duration, and reporting of AF have produced
methodological limitations impacting on the validity of interstudy comparisons. Standardization of these parameters may, in
future, allow us to further evaluate clinical endpoints and establish the eﬃcacy of these techniques.
1.Introduction
Atrial ﬁbrillation (AF) is associated with signiﬁcant mor-
bidity and mortality in both medical and surgical patients.
Results from the Framingham Heart study found AF to be
associated with an overall lifetime risk of 1 in 4 adults aged
40–95 years or 1 in 6 of those without previous myocardial
infarction or congestive cardiac failure [1]. Coronary artery
bypass grafting alone has been associated with an incidence
of AF reaching 30% in multicentre observational studies
[2, 3] and may be signiﬁcantly higher following valvular
surgery [4]. More importantly, postoperative AF has been
found to triple the risk of death from cardiac causes and
quadruple the risk of stroke and other disabling embolic
events[2].
The original “corridor” procedure for the treatment of
AF was described by Guiraudon in 1985, but for a number
of reasons was soon superseded by the “Maze” procedure as
described by Cox et al. in 1991 [5, 6]. His work outlined
a series of “cut and sew” lesions which aimed to direct
electrical impulses in one direction through the atrium,
disrupting the macro reentrant circuits which allow the
development and propagation of AF. This procedure, whilst
eﬀective,wasnotwithoutitscomplications,andtheresultant
inability to mount a tachycardic response to exercise and
left atrial dysfunction led to two further adaptations of this
procedure culminating in the Cox Maze III lesion set [5].
These modiﬁcations resulted in an improvement in the rates
of postoperative sinus rhythm and long-term sinus node
function, leading to fewer pacemaker implantations after
surgery. Furthermore, improved long-term atrial transport
function, low rates of arrhythmia recurrence, and a low
incidence of thromboembolic complications could support
the application of the maze procedure in patients where
nonsurgical therapy has failed.
H o w e v e r ,t h em a z ep r o c e d u r eh a sb e e nl i m i t e dt oa
few specialist centres due to its technical diﬃculty and a
lack of widespread experience. Its requirement for median
sternotomy and cardiopulmonary bypass (CPB) also fuelled
the search for an alternative, less invasive technique. Surgical
ablative devices and modiﬁcations to the lesion set now
allow, in some cases, for a minimally invasive, oﬀ-pump,
beating heart approach. However,it is important to note that
at the present time these techniques may not attain a similar2 Cardiology Research and Practice
level of long-term freedom from AF as the classical Maze III
procedure [7].
This review describes the evolution of AF surgery, from
“cut and sew” to ablative techniques, using novel energy
delivery systems. We discuss its role both as a standalone and
concomitantprocedureand highlightthecurrentindications
and outcomesfor the most common techniques described in
the literature.
2.CorridorProcedure
Originally proposedby Guiraudonin1985,thecorridorpro-
cedure isolated the atria, allowing only a single conduction
pathway between the sinoatrial (SA) and atrioventricular
(AV) node, thereby re-establishing a regular ventricular
rhythm [8]. The procedure achieved good rates of freedom
from AF, however isolation of the atria from the SA node
allowed the remaining atria to continue to ﬁbrillate and did
not restore atrial transport function. The thromboembolic
risk ofAFthereforeremained and, assuch,the procedurehas
since been superseded by the “cut and sew” Maze.
3.The “Cutand Sew”Maze
Cox et al. described the original maze procedure in 1991
[6, 9]. Between September 1987 and 1994, a total of 123
patients were included in his trial. The ﬁrst 32 patients
underwent the Cox-Maze I procedure, however, at late
followup several limitations were revealed. The ﬁrst of
these was the inability to generate an appropriate sinus
tachycardia in response to exercise. This was felt to be a
consequence of placing the surgical incision at the junction
of the superior vena cava (SVC) with the right atrium
(RA) too anteriorly. This incision was removed in Maze II
procedure; however, several other modiﬁcations necessary
to maintain the eﬃcacy of Maze I resulted in signiﬁcantly
more technical diﬃculty with this procedure. The left-sided
exposure with MazeIIwas verylimited andrequireddivision
of the SVC. Furthermore, it became necessary to patch
the SVC with autologous pericardium to prevent stenosis.
Additionally, Maze II resulted in a similar degree of left
atrial (LA) dysfunction as Maze I. Division of Bachmann’s
bundle during both procedures markedly slowed inter-atrial
conduction, in turn causing synchronous contraction of the
left atrium and ventricle, eliminating the LA “kick”. Further
modiﬁcation to the lesion set therefore culminated in Maze
III procedure, which both eliminated the need for an SVC
patch and improved left-sided exposure [5].
The “cut and sew” Maze III procedure has been asso-
ciated with good long-term results, in Cox’s original study
93% of patients remained free from AF or ﬂutter recurrence
at 8.5-year followup and all recurrences were successfully
cardioverted with one antiarrhythmic drug [10]. Similarly
encouraging results have been published by other groups
(Table 1).
Despite its eﬃcacy at terminating AF, several aspects of
the Maze III procedure have limited its uptake to a few spe-
cialist centres. Primarily this reﬂects the technical diﬃculty
ofthepr ocedur eandther equir ementformediansternotom y
and cardiopulmonary bypass. Many surgeons feel that such
an approach is too invasive for the sole treatment of cardiac
arrhythmia, limiting it to patients undergoing concomitant
coronary or valve surgery. In addition, even with the Maze
III procedure, the early and late eﬀects on atrial mechanical
function have raised concern [11]. However, as yet the
long-term eﬀects of reduced atrial contraction on potential
thromboembolic complications have not been studied in
depth and remain a focus for further research.
4.Surgical Ablationand the CoxMaze IV
The introduction of novel energy delivery systems (Table 4)
allowed for the development of Maze IV procedure as
described by Damiano and Gaynor in 2004 [12]. This
provided the potential advantages of a reduction in postop-
erative morbidity, without reducing eﬃcacy or completeness
of the lesion set. During Maze IV procedure, whilst both left
and right arteriotomies are performed surgically, radiofre-
quency ablation reproduces many of the surgical incisions
of Maze III procedure with additional cryoablation added to
complete the lesion set to the mitral annulus (Figures 1(a)
and 1(b)). In their original study, Gaynor and colleagues
reported a93.1%freedomfromAFat6monthsbutadmitted
that followup at the time of publication was insuﬃcient
to allow comparison to Maze III lesion set [13]. Since this
time various permutations on Maze IV lesion set have been
implemented, these are summarised in Table 3.
5.RadiofrequencyAblation
I nt h ea t t e m p tt oa c h i e v eal e s si n v a s i v et e c h n i q u ec a p a b l e
of producing results comparable to the cut and sew Maze III,
proceduretheuseofradiofrequency(RF)ablationhasgrown
rapidlyinpopularity.RFtechniquesarecapableofproducing
a continuous and transmural lesion set in conjunction with
a reduction in both operating time and technical diﬃculty
[14].Whilst RFablationissafe, itshouldbecarefullyapplied,
avoiding direct contact with the pulmonary veins (PV),
to prevent PV stenosis. The risk of intercavity thrombus
formation and the potential for collateral oesophageal or
circumﬂex injury should also be considered and bipolar
devices used where possible [14].
Along with the advent of this innovation came multiple
changes to the lesion set creating diﬃculties in evaluating its
results against those of the “cut and sew” Maze III (Table 2).
In their multicentre study closely replicating Maze III lesion
set, Raman et al. achieved excellent results with concomitant
RF ablation reporting 84% freedom from AF at 3 months,
90% at 6 months, and 100% at 12 and 18 months [15].
Notably however, only 15 of the 110 patients had reached
12-month followup at the time of publication and following
the procedure all patients were kept on a regimen 200mg
amiodarone for 6 months unless contraindicated.
Pulmonary Vein Isolation (PVI) alone has been per-
formed by a number of groups and has produced good
resultsinparoxysmalAF;howevertheresultsinlongstandingCardiology Research and Practice 3
Table 1: Freedom from AF at ﬁnal follow up after “cut and sew” maze procedure.
Study Type of procedure Number of patients Duration of followup
(years) (Mean ± SD)
Freedom from AF at
ﬁnal followup (%)
Cox et al., 1996 [10] Lone maze 178 8.5 93
L¨ onnerholm et al., 2008 [11]L o n em a z e 5 2 4 . 7± 1.0 86.5
Prasad et al., 2003 [75]
Lone maze 98 5.4 ± 3.0
79.6 (no AAD∗)
95.9 (with AAD)
Concomitant 86 5.4 ± 2.7
73.4 (no AAD)
97.5 (with AAD)
Ad et al., 2009 [59]
Lone Maze 33 9.8 ± 7.7 91.0
Lone and Concomitantmaze 76 9.8 ± 7.7 84.0
Stulak et al., 2007 [7] Concomitant 56 0.7 (2.75–7)∗∗ 92.0
Gaynor et al., 2005 [13] Concomitant 253∗∗∗ 6.1 (0.5–15.5)∗∗ 92.2
∗AAD: Anti Arrhythmic Drugs, ∗∗median (range), ∗∗∗includes 33 Maze I, 16 Maze II, 197 Maze III, and 30 Maze IV.
Table 2: Summary of results obtained by radiofrequency ablation.
Study N Lesion set Type of AF and
aetiology
Concomitant or
lone surgery
Mean followup
± SD (months)
Freedom from
AF at mean
followup (%)
Overall
mortality at last
f/u (%)
Srivastava et al.,
2008 [16]
160 Overall
Persistent >3
months Rheu
matic
Concomitant 40
40 Biatrial 62.5 10
40 LA only 57.5 7.5
40 PVI 67.5 10
40 None 20.0 5
Wang et al.,
2009 [17]
299 Overall
Permanent Concomitant 28 ± 5
85.0 2.3
149 LA+ cavotricuspid 85.2 1.3
150 Biatrial 84.1 4.7
Chiappini et al.,
2004 [18] 40 CM III Chronic Concomitant 16.5 ± 2.5 88.5 at last f/u 7.5
Beukema et al.,
2008 [19] 285 Modiﬁed Maze
(biatrial) Permanent Concomitant 43.6 ± 25.4 57.1 at last f/u 27.4%
Topkara et al.,
2006 [20]
Endocardial 82.9%
epicardial 17.1%.
Variable lesion set
Paroxysmal
Concomitant
and Lone
Last f/u 24
months
75.3
Not speciﬁed
for RF only
168 Persistent
Lone
AF have been suboptimal with signiﬁcantly higher recur-
rence rates reported [31–34]. Several small studies report
freedom from AF after RF PVI ranging from 87% at 6
months [31] and 71% at 3.3-year mean followup [35].
When combined with left atrial appendage (LAA) excision,
ligament of Marshall (LoM) or ganglionic plexus ablation,
PVI has yielded rates of freedom from AF ranging from 87–
87.5%at6months[31,32]and65%at1-yearfollow up[36].
As with all ablative techniques, these interstudy varia-
tions in success rate must be considered cautiously whilst
taking into account the criteria for diagnosis and reporting
of AF. The move from telephone questionnaire and one-oﬀ
ECGs to long-term monitoring after the publication of the
heart rhythm society (HRS) consensus guidelines may have
inﬂuenced reporting of AF recurrence rates. Incompletely
transmural lesions may also explain the higher recurrence
rates seen with RF over the “cut and sew” technique.
Innovations such as cooled tip and bipolar electrodes have
allowed for greater eﬃciency with RF ablation; however,
conﬁrmation of transmurality remains a problem. Factors
related to the electrode (duration of application, contact
with tissue), the myocardial tissue (tissue convection and
conductance),andthesurroundingenvironment(convective
cooling due to blood ﬂow) all play an important role
[14]. As such, it is diﬃcult to produce uniform settings
for each instrument and the need for feedback to conﬁrm
transmurality remains important. Whilst some of these
groups report the use of impedance measurements or entry
and exit stimulation as conﬁrmatory mechanisms [36, 37]
others lack any form of feedback [31, 35, 38]. It is also
possible that even in the presence of complete transmurality
early postoperative reinnervation of the myocardium may4 Cardiology Research and Practice
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Table 4: Comparison of ablative modalities.
Transmurality Endocardial Epicardial Advantages Potential
complications
Use outside
research and
clinical trials
Accuracy
(width/depth
ratio)
Radiofrequency
Variable
improved with
bipolar devices
Yes Yes Able to produce fast and
eﬀective lesion set
Risk of inter-cavity
thrombus formation,
char formation,
collateral damage to
circumﬂex artery and
oesophagus and PV
stricture
Yes Moderate
Cryoablation Good Yes Yes
Preserves cellular
architecture and capable
of producing mitral and
tricuspid isthmus
lesions.Minimal
collateral damage, able
to produce well-
demarcated lesion,
adheres to myocardium
to produce good contact
with tissue, low risk of
bleeding or perforation
Potential risk of
coronary artery
damage
Yes Moderate
Microwave Variable Yes Yes
Lower risk of
thromboembolism,
minimalchar formation,
and minimalcollateral
damage
Potential for
circumﬂex artery
damage
Yes Good
High Frequency
Ultrasound Excellent No Yes
Advantage of fast,
transmuralepicardial
lesions with theoretical
potential to visualize
wall thickness and
perform tailor made
lesion
Risk of collateral
damage and
perforation
No Poor
Laser Excellent Yes Yes
Able to produce fast,
deep, and uniform
lesions
Risk of crater
formation and
perforation
No Poor
precipitate AF recurrence. In 2006, Kangavari and colleagues
highlighted an upregulation of nerve growth factor (NGF)
following RF ablation [39], potentially resulting in nerve
sprouting and AF recurrence. Further work is now required
to identify whether this phenomenon translates into a
clinically signiﬁcant eﬀect.
6.Cryoablation
Cryoablative devices use argon and helium delivered under
high pressure to producing cooling of −55 to −60◦C. This
initially results in cellular disruption which is followed by
inﬂammation and ﬁbrosis to produce a homogeneous, full
thickness disruption to cellularity without causing stromal
damage [14].
The results with cryoablation have been variable from
60% at 3.6-year followup [40] to 82.3% at 3.8-year followup
[41]. With their more extensive lesion set, Funatsu et al.
report a freedom from AF of 84.1% and 80.2% at 3- and
5 years, respectively [42]. These results can be seen to
be comparable to RF ablation, however outcomes of large
directly comparative studies are still awaited [43].
Several advantages have been described with the use
of cryoablation over other ablative techniques. The ﬁrst of
these is a visual conﬁrmation of transmurality provided by
frosting along the ablation line. Secondly, by maintaining
the integrity of vascularity and preserving collagen, less
damage to the surrounding tissues has been reported
[14]. Cryoablation also causes signiﬁcantly less endocardial
thrombus volume potentially reﬂecting the preservation of
the endothelial cell layer. Additionally, cryoablation has
practical beneﬁts, technically enabling the surgeon to create
an isthmus lesion from the pulmonary veins to the mitral
annulus and allows an electrical isolation of the atrium that
cannot easily be achieved with RF or microwave ablation.
7.MicrowaveAblation
Microwaveablationproducesawell-demarcated area ofther-
mal injury and is not only capable of producing transmuralCardiology Research and Practice 7
(a)
(b)
Figure 1: (a) Left atrial Maze III lesionset. (b) Right atrial Maze III
lesion set.
lesions when applied to the epicardial surface but may be
more easily applicable to minimally invasive techniques.
However, the overall results for this new technology have
been less encouraging (Table 3). Whether this is a reﬂection
of the technology or the quality of lesion set is uncertain.
Current data reﬂects a combination of LA and biatrial
procedures, each with slightly diﬀerent patterns of ablation
andindiﬀerenttypesofAF.Inatrialof41patients,Vicoland
colleagues performed a series of LA endocardial ablations in
patients with chronic secondary AF (>1 year) undergoing
concomitant cardiac surgery via median sternotomy [21].
Whilst the 1-year freedom from AF was 80%, by a mean
follow up of 5.37 years only 39% had long-term freedom
from AF. Similarly, thoracoscopic studies have reported
relatively high incidences of AF recurrence. Both Puritt
[22] and Koistenen [44] combined a population of lone
paroxysmal, persistent and permanent AF in their studies.
Pruitt reported freedom from AF to be 42% at long-term
followup (mean 23.1 months) whereas Koistinen reported
59% at 1 year. A lack of homogeneity is clearly exempliﬁed
here in both patient selection and treatment strategies.
Pruitt’s group performed PVI alone, ligating the left atrial
appendage (LAA) only when it was found to be enlarged,
whereas Koistinen performed PVI with an LAA extension,
ligating the LAA in 85% and including a right atrial and
intercaval line in 25%. However, their published results
reﬂect the group as a whole, and it is therefore impossible to
identify the precise cause of suchhighrates ofAF recurrence.
It is indeed possible that part of this explanation may
arise from inadequacies in the technology itself. “Heat
sink” secondary to poor contact with atrial tissue and
the absence of a feedback mechanism may have resulted
in inadequate transmurality and incomplete disruption of
reentrant circuits. Alternatively, these results may reﬂect
a drawback in their study design. It is recognised that
structural remodelling seen in longstanding AF makes PVI
alone suboptimal and necessitates a more extensive lesion
set of the kind described in the Maze III procedure.
Furthermore, by limiting ablation lines to the LA, the
potential for development of RA ﬂutter or macro-reentrant
circuitsisnotexcluded,potentiallyexplainingadegreeofthis
recurrence. This data should therefore be interpreted with
caution, calling for a more homogeneous approach to study
design before deﬁnitive conclusions can be drawn.
8.High-FrequencyUltrasoundAblation
High-Frequency Ultrasound (HIFU) creates localised hyper-
thermic lesions and is capable of producing transmurality
when applied epicardially. It is a relatively new ablative
modality and as such current guidelines from the National
Institute for Health and Clinical Excellence (NICE) only
approve it for use in specially organised audit or research
[45]. Current results are however encouraging, reporting
a freedom from AF of 85% at 6 months [46, 47]a n d
86.2% at 18 months [48]. However, evidence of oesophageal
and mediastinal injury has been documented following
HIFU catheter ablation, with one group reporting a case of
fatal atriooesophageal ﬁstula reported at 31 days following
this technique [49]. Whilst no such problems have been
identiﬁed with concomitant HIFU ablation during other
cardiacsurgeryapotentialforcollateraldamageisrecognised
in the literature [45].
Despite these concerns, the theoretical possibility of
combining the imaging beneﬁts of ultrasound with ablative
techniques could potentially produce an eﬀective device
which not only allows the surgeon to quantify atrial wall
thickness and deliver a tailor made ablation, but also
conﬁrms transmurality [14].
9.LaserAblation
Laser ablation uses high-energy optical beams to create a
narrow, well-demarcated, and nonarrhythmogenic thermal
lesion [14]. Animal studies have demonstrated that laser
ablation is able to produce rapid and histologically trans-
mural lesions capable of electrophysiologically isolating the
atrium[20].Whilstthereisalackoflargemulticentrehuman
trials in this modality, smaller studies have reported positive
results. Hamman and coworkers examined 28 patients with8 Cardiology Research and Practice
variable types of AF. They performed a limited left-sided
lesion set in patients with paroxysmal AF but extended this
to include right-sided lesions in those with persistent or
permanent AF. At a mean followup of 18 months, 76%
were free from all tachyarrhythmias. At present, no device-
relatedcomplicationshavebeenreportedintheabovestudies
however, some potential concerns have been raised with this
technology. Poor visibility of the scar necessitates careful
monitoring of thepathand extentof thelesion, and itshould
be remembered the excess heat produces the potential for
crater formation, perforation, and tissue loss [14].
10.ThoracoscopicMaze Procedures
T h ei n v a s i v en a t u r eo fm e d i a ns t e r n o t o m yc o m b i n e d
with endocardial ablation, atriotomy, and cardiopulmonary
bypass has historically limited the standalone surgical
treatment of AF. Over the past decade, the development
of ﬂexible, epicardial ablative devices has allowed for the
evolution of minimally invasive procedures, thereby oﬀering
a surgical strategy in symptomatic patients failing catheter
ablation. By reducing surgical trauma, totally thoracoscopic
approaches oﬀer the advantage of improved postoperative
recovery and a reduction in hospital stay. More recently, the
application of robotic techniques may oﬀer both improved
surgical dexterity and increased visualization [50, 51].
However, early thoracoscopic techniques have been sub-
ject to a number of limitations. The use of a range of ablative
modalities, as well as the variability and limited nature of
the lesion set, has led to diﬃculties in interpretation of
the overall results. Whilst freedom from AF reaching 91%
has been obtained at 3 and 6 months [52, 53], long-term
followup has been less encouraging [22, 36, 54]. Presently,
thoracoscopic modalities are also largely limited to PVI
in patients with paroxysmal AF. Furthermore, whilst less
invasive than median sternotomy, the majority of these
procedures still require minithoracotomy, carrying with it
its own postoperative morbidity [32]. Finally, thoracoscopic
and robotic techniques are associated with higher operative
cost and a steep learning curve for the surgeon [55];
consequentially prolonging operative time and limiting their
application to centres with suﬃcient resource.
The role of thoracoscopic and robotic procedures in the
surgical management of AF therefore remains an exciting
area of development. At present whilst it should be con-
sidered in the treatment of pAF, further larger studies are
required to quantify its long-term outcomes.
11.LesionSets
Consideration of the pathophysiology of the underlying
arrhythmia is vital when deciding upon an appropriate
treatment plan[56]. The onset and typeof AF (primary/lone
AF versus secondary AF), right and left atrial dimensions are
of paramount importance in determining a surgical strategy.
Forexample,itiswellrecognisedthatpatientswithpersistent
AF have poorer results with PVI in comparison to those
with paroxysmal AF. In 1998, Ha¨ ıssaguerre et al. mapped
the majority of triggering foci in paroxysmal AF to the
pulmonary vein ostia [57] and demonstrated the potential
for RF ablation of these foci to treat AF. In permanent
or persistent AF however, the self-perpetuating nature of
the arrhythmia and presence of macro-reentrant circuits
eliminates the requirement for these triggers to repeatedly
initiate the arrhythmia [56]. As such, the physical size of
these circuits in comparison to the triggering foci seen in
paroxysmal AF often necessitates the need for intervention
beyond PVI alone.
Atrial size has also recurrently been implicated as an
independent risk factor for the recurrence of AF following
surgical ablation [58–60]. In patients with a normal RA, the
prolonged refractory period only allows for the development
of a single macro-reentrant circuit. However, patients with
RA enlargement have the potential for the development of
multiple macro-reentrant circuits and as such biatrial inter-
vention should be considered [56]. Conversely, in secondary
AF without concomitant RA enlargement, macro reentrant
drivers are mainly conﬁned to the LA and consequently
isolated LA procedures may be suﬃcient. However, it should
be noted that standalone LA procedures do not eliminate the
potential to generate RA ﬂutter. An additional cavotricuspid
“ﬂutter lesion” may therefore be required in LA only lesion
sets [56].
12.PermanentAF
Permanent AF is associated with changes in the atrial
substrate including a reduction in the ERP, shortened
action potential and wavelength. Furthermore, myocardial
ﬁbrotic changes slow conduction velocity and perpetuate
the arrhythmia. As such, permanent AF presents further
challenges in maintaining long-term freedom from the
arrhythmia following surgical intervention. Isolated PVI is
not recommended in the treatment of primary persistent
AF due to high rates of AF recurrence [61]. Higher failure
rates have also been seen in the treatment of primary
chronic AF with standalone left atrial procedures. Following
their standalone LA radiofrequency lesion set, Speziale et al.
describe a recurrence rate of 18.5% in persistent lone AF
compared to 5.3% in paroxysmal AF at 6-month followup
(P<. 001) [31]. Similarly, Cui et al. report a 67.7% freedom
from AF at 12 months in long-standing persistent “lone”
AF compared to 80% in paroxysmal “lone” AF following
minimally invasiveRFablation[62].Ha¨ ıssaguerreandCoxet
al. provide a potential explanation to this recurring problem
basedonachangeintherightatrialsubstrate. Mappingatrial
electrograms in the majority of patients reveals prolonged
right atrial AF cycle lengths, reﬂecting a driving mechanism
from the LA. However, approximately 20% of patients with
persistent AF exhibit shorter cycle lengths indicating a right
atrial driver[63]. It follows that shorter AF cyclelengths may
allow for more than one macro reentrant circuit to be set
up and as such neither standalone LA procedures nor the
addition of a right atrial cavotricuspid lesion will prevent
AF recurrence [56, 63]. In such patients, a complete biatrial
Maze III procedure may be the only way to ensure long-term
freedom from AF.Cardiology Research and Practice 9
13.AtrialSizeReduction
The concept of an atrial critical mass above which the
propagation and maintenance of AF is favoured was origi-
nally proposed by Garrey in 1914 [64]. More recent work
has quantiﬁably demonstrated this hypothesis, with both
increased left atrial area [58, 65] and reduced eﬀective
refractory period (ERP) favouring sustained AF [65]. By
reducing the area in which the macro reentrant circuits that
propagate AF can be set up, atrial reduction surgery may
therefore potentially sustain freedom from AF. In their study
of 80 patients with enlarged left atrium (ELA) undergoing
concomitant atrial reduction at the time of the CryoMaze III
procedure, Marui and colleagues demonstrate a signiﬁcant
improvement in long-term freedom from AF at both 12 and
24 months [66]. Scherer et al. also show improved freedom
from AF in patients undergoing concomitant LA reduction
(61.1 versus 70% at 36 months), although this did not
reach statistical signiﬁcance [67]. The overall results of atrial
reduction surgery found within the literature are outlined
in Table 5. A wide range in freedom from AF is seen here
(58–100% at last followup), reﬂecting the variability in the
durationofpreoperativeAF,atrial reductiontechniquesused
andtheconcomitantproceduresperformed. Whilst arolefor
atrial reduction procedures is therefore apparent in patients
with ELA, further evidence is required to deﬁne clear clinical
guidelines.
14. SuccessRateMonitoring
With the advent of a multitude of new technologies it has
becomemoreimportantthanevertoproduceadrivetowards
a homogeneous deﬁnition of the criteria constituting AF
recurrence or surgical failure. A number of studies report
results based on telephone questionnaires and single ECG
strips with a lack of long-term monitoring, others report
surgical success based upon postoperative thromboembolic
events without deﬁning recurrence at all. This has been the
focus for a number of criticisms surrounding a potential
over-representation of success rates with the Cox Maze III
“cut and sew” procedure [36]. Since the publication of the
HeartRhythmSocietyexpertconsensusguidelines[73]ther e
is now a move to report any period of AF or ﬂutter recorded
for greater than 30 seconds on Holter monitoring as a
recurrence of AF. However, the use of long-term monitoring
devices is not without its associated shortcomings. Patient
compliancemay bepoor, and in those systems requiring self-
triggering, asymptomatic paroxysms may not be adequately
captured. Some long-term systems solely determining AF on
the basis of R-R variability may not register paroxysms that
do not produce such a variation. Conversely, some long-
term systems may register irregular premature atrial beats as
AF, resulting in premature atrial beats caused by nonisolated
triggers outside the PV cuﬀ being recorded as AF recurrence
[59]. When assessing the current data and planning further
work, one should therefore keep this under consideration.
The question has also been raised that if episodes of un-
sustained AF are asymptomatic and last between 30 seconds
and 5mins, are these of clinical signiﬁcance? The answer
to this certainly involves a number of factors and in part
will depend on the frequency of these episodes and the
risk of thromboembolic complications although relevant
information appears to be sparse and inconclusive. Indeed,
quality of life (QoL) scores have been shown to improve
signiﬁcantly following surgery for AF, with health-related
QoL scores equivalent to an age-matched general population
at long-term followup (mean 4.6 years) [74]. We therefore
believe that whilst clinical signiﬁcance should be considered
when discussing AF recurrence rates, we must be cautious to
comply with uniform reporting criteria to allow meaningful
interstudy comparisons to be made.
15.Anticoagulation
The duration of anticoagulation following AF surgery either
by ablative or “cut and sew” techniques remains variable
within the literature. Surgical ligation of the left atrial
appendage and lower AF recurrence rates have resulted
in low rates of thromboembolic complications following
surgical intervention [75, 76] and whilst concomitant valve
surgery may necessitate the need for permanent anticoagula-
tion,varying strategieshavebeenimplementedinstandalone
procedures. In their 1999 study of the “cut and sew” maze
procedure reporting a 0.4% stroke rate at 11-year followup,
Coxandcolleaguesdidnotadvocateanticoagulationwithout
a prior history of thromboembolism. Whilst these results
are encouraging, a consensus for short-term anticoagulation
can be found throughout the literature. As such, in 2008
Henry and Ad produced guidelines on the management
of anticoagulation following the Maze procedure. These
recommendations advise all patients to be commenced on
warfarin for 3 months postoperatively unless otherwise con-
traindicated. Before the discontinuation of anticoagulation,
conﬁrmation of sinus rhythm should take place by means
of long term holter monitoring. At this point, any patients
found to be in AF should continue anticoagulation until this
has been resolved [24].
16.Summary
Surgical treatment for AF has been available for two decades
since the original description of the Cox-Maze procedure.
Technical advances, including novel energy delivery systems
for the creation of atrial lesion sets, and a better under-
standing of the pathogenesis of AF have also validated
surgical ablation as an eﬃcacious concomitant procedure
and, occasionally, as a standalone treatment. These advances
have paved the way for the development of less invasive
approaches, some of which eliminate the need for median
sternotomy and CPB.
However, comparative studies of patients undergoing
surgical ablation versus either established antiarrhythmic
therapy or between diﬀerent lesion sets and varying energy
sources have endured certain methodological limitations.
AF deﬁnition (and duration) has remained variable in
numerous studies, when it is well established that AF burden
can signiﬁcantly inﬂuence outcomes. Secondly, the most10 Cardiology Research and Practice
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common endpoint, freedom from AF after surgery, must
be evaluated in view of the use (or not) of antiarrhythmic
medications and the duration of followup. Finally, what
is often considered as procedural success or “cure” for
symptomatic persistent AF may occasionally represent its
transformation to silent paroxysmal AF that has not been
adequately captured. Many of these issues are highlighted
in the systematic review by Khargi and colleagues, who
demonstrate that whilst sinus rhythm conversion rates in
patients undergoing the conventional Cox-Maze III versus
alternative energy sources are equivalent, there is signiﬁcant
heterogeneity between studies [77].
Despite this, there is a consensus towards the usefulness
of surgical AF ablation especially in patients with structural
heart disease. The report of the Heart Rhythm Society
(HRS) Task Force indicates that AF ablation must be oﬀered
to all patients undergoing other cardiac surgery, as long
as the risk of this concomitant procedure remains low,
there is a reasonable chance of success, and the surgeon
has appropriate experience in antiarrhythmia surgery. With
r e s p e c tt os t a n d a l o n es u r g i c a la b l a t i o n ,t h eH R ST a s kF o r c e
suggests that it may be considered for symptomatic patients
willing to undergo surgery, who are either not candidates
for catheter-ablation or in whom catheter ablation has failed
[20]. However, since these recommendations were published
in 2007 there have been no robust multicentre randomised
clinical trials to overcome some of the reported limitations
or to evaluate tangible endpoints such as functional capacity
and long-term mortality.
Despite encouraging long-term success rates with open
interventions, the invasiveness of median sternotomy in the
standalone treatment of AF continues to remain an impor-
tant consideration. Conversely, whilst percutaneous catheter
based techniques oﬀer a minimally invasive approach, the
long-term freedom from AF may be variable. As such,
there has been growing interest in establishing a minimally
invasive approach, either thoracoscopically or by minitho-
racotomy which may potentially oﬀer a “middle ground”,
combining the success rates of conventional open surgery
with reduced procedural trauma. However, at the present
time the application of these techniques is limited to a few
specialist centres, and long-term outcome data is awaited
before recommendations can be made.
In conclusion, this review highlights the widespread
acceptance of both “cut and sew” and ablative techniques in
therestorationofsinusrhythm,viabothopenandminimally
invasive approaches. Equally we raise the need for well-
conducted studies to establish a comparative eﬃcacy in the
diﬀerent types of AF and more accurately evaluate clinical
endpoints. The advances in minimally invasive technologies
androboticsrenderthefutureof surgicalAFmanagement an
encouraging prospect.
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